Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MetMAb plus erlotinib versus erlotinib plus placebo in advanced non-small cell lung cancer (Phase II)
2008-006939-13Phase 2Completed
- Sponsor
- Genentech
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing MetMAb + erlotinib with Placebo + erlotinib (2 arms). Primary endpoints: Progression-free survival (PFS) in MET-positive tumors and Progression-free survival (overall population). Started Apr 2009; status: completed.
02
Drugs
onartuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-006939-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006939-13.